The historical rank and industry rank for KPC Pharmaceuticals's FCF Margin % or its related term are showing as below:
SHSE:600422'
s FCF Margin % Range Over the Past 10 Years
Min: -5.08 Med: 2.01 Max: 8.67
Current: -5.08
During the past 13 years, the highest FCF Margin % of KPC Pharmaceuticals was 8.67%. The lowest was -5.08%. And the median was 2.01%.
SHSE:600422's FCF Margin % is ranked worse than 67.54% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs SHSE:600422: -5.08
KPC Pharmaceuticals FCF Margin % Related Terms
KPC Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for KPC Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KPC Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where KPC Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPC Pharmaceuticals (SHSE:600422) has a FCF Margin % of -77.26% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on KPC Pharmaceuticals and its competitors. According to the industry distribution chart, KPC Pharmaceuticals ranks #645 out of 955 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is KPC Pharmaceuticals' FCF Margin % too high?
KPC Pharmaceuticals' current FCF Margin % is -77.26%. Based on the distribution chart, KPC Pharmaceuticals ranks #645 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, KPC Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, KPC Pharmaceuticals ranks #645 out of 955 companies for FCF Margin %. This places KPC Pharmaceuticals in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on KPC Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KPC Pharmaceuticals's current FCF Margin % is -77.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥11.77, compared to a current price of ¥7.70 — trading 34.6% below its estimated fair value. The current FCF Margin % is -77.26%. KPC Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current FCF Margin % is -77.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?
Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥7.70 is trading 34.6% below its estimated GF Value™ of ¥11.77.
GuruFocus considers KPC Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for SHSE:600422:
FCF Margin %: -77.26%
GF Value™: ¥11.77 vs. price of ¥7.70 (34.6% below fair value)
No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
62GF Score
Get the complete analysis for SHSE:600422
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600422 has been successfully added to your 
